Biocontainment Research support services core

生物安全研究服务：摘要 12个NIAID资助的区域生物遏制实验室（RBL）中的每一个都有 区分和补充研究能力，以促进传染病和 生物防御研究乔治梅森大学（GMU）的RBL，也被称为生物医学 研究实验室（BRL）专注于集成和开发器官芯片 (OOC)用于治疗的体外和动物模型测试的封闭模型， 疫苗产品筛选和评价。此外，GMU拥有一套全面的 支持BSL-3病原体和选择剂气溶胶的先进研究仪器 小动物的暴露以及器官、组织和分子水平的攻毒分析 问题研究GMU的专业知识补充了这些遏制能力， 蛋白质组学、代谢组学和纳米技术以及开发平台的跟踪记录 这些技术已经从实验室过渡到市场。 GMU拟议的生物防护研究支持服务核心将包括：1） 微生理系统（MPS）核心和2）高级动物研究（AAR）核心。 MPS平台将代表至少九个不同的器官系统， 用于至少十二种优先病毒和细菌病原体的相关人源细胞类型。 伴随的测定包括病原体定量的检测限、炎性 将为每个模型开发感染背景下的负荷和器官损伤。 核心中集成了额外的高通量器官芯片（OOC）和类器官平台 将提供更多功能，通过多个平台验证结果， 的发现AAR核心将集成一整套最先进的技术， 传染病专业知识，通过尖端技术加速对策开发 用于铅优化、给药、毒性筛选、安全性评估、疗效、免疫 调制和生物分布。 核心将配备BRL的研究科学家，以支持内部调查人员， 作为RBL网络和制药和生物技术合作伙伴的资源 公司;联邦，州和地方机构;和学术机构进行传染病 疾病和生物防御研究和对策发展。

BIOCONTAINMENT RESEACRCH SERVICES: ABSTRACT Each of the twelve NIAID funded Regional Biocontainment Laboratories (RBLs) have distinguishing and complementary research capabilities to advance infectious disease and biodefense research. George Mason University’s (GMU)’s RBL, also known as the Biomedical Research Laboratory (BRL) has focused on the integration and development of organ-on-a-chip (OOC) models in containment to bridge in vitro and animal model testing for therapeutics and vaccine product screening and evaluation. Furthermore, GMU has a comprehensive suite of advanced research instrumentation to support BSL-3 pathogen and select agent aerosol exposures in small animals as well as organ, tissue, and molecular level analysis of challenge studies. These capabilities in containment are complemented by GMU’s expertise in proteomics, metabolomics, and nanotechnology as well as a track record of developing platform technologies that have transitioned from the bench to market. The proposed Biocontainment Research Support Services Core at GMU will include 1) a Microphysiological systems (MPS) core and 2) an Advanced Animal Research (AAR) core. The MPS platforms will represent at least nine different organ systems with representation by relevant human-derived cell types for at least twelve priority viral and bacterial pathogens. Accompanying assays including the limit of detection for pathogen quantification, inflammatory burden, and organ damage in the context of infection will be developed for each model. Additional high throughput organ-on-a-chip (OOC) and organoid platforms integrated in the core will provide added functionality, validation of results through multiple platforms, and accelerated discovery. The AAR core will integrate a comprehensive set of state-of-the-art technologies and infectious disease expertise to accelerate countermeasure development through cutting-edge approaches for lead optimization, dosing, toxicity screens, safety assessment, efficacy, immune modulation, and biodistribution. The cores will be staffed with research scientists in the BRL to support internal investigators and serve as a resource for the RBL network and partners from pharmaceutical and biotechnology companies; federal, state, and local agencies; and academic institutions conducting infectious disease and biodefense research and countermeasure development.